Alembic Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,848Cr
- +4.4% YoY
- −1.5% QoQ
- Net profit
- ₹202Cr
- +28.7% YoY
- +53% QoQ
- Margin
- 12%
- −3 pp YoY
- −4 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Alembic Pharmaceuticals Ltd Q4 FY26 key numbers
- Revenue
- U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).
As stated in Alembic Pharmaceuticals Ltd's Q4 FY26 earnings call transcript · published 24 May 2026. Reported figures, not investment advice.
The short version
Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.
From Alembic Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions.
- U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).
- Rest of World (ex-U.S.) markets projected to grow 15%+ driven by new product launches and expanding footprints.
- API business anticipated to grow around 10%, supported by volume increases.
- India business aims to improve growth momentum, targeting growth closer to the overall market.
- New product launches, especially Day 1 and First-to-File opportunities, along with contract manufacturing, will support volume growth.
2 more points from Alembic Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex.
- The branded business, including U.S. specialty branded operations like Pivya, does not require significant capex; investments are primarily in in-licensing products.
- For FY '27, capital expenditure is expected in the range of INR 300-350 crores, focused on capacity expansion, debottlenecking, and replacement capex.
- There will be continued, though measured, R&D investments (~INR 750-800 crores) to support complex products and expansion of the branded business.
2 more points from Alembic Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Alembic Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
What the Q4 FY26 call signalled
1 of 3 strong
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Alembic Pharmaceuticals Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,848 | 1,770 | +4.4% | 1,876 | -1.5% |
| Operating profit (EBITDA) | 228 | 271 | -15.9% | 292 | -21.9% |
| Operating margin | 12% | 15% | -3 pp | 16% | -4 pp |
| Profit before tax | 119 | 192 | -38% | 162 | -26.5% |
| Net profit (PAT) | 202 | 157 | +28.7% | 132 | +53% |
| EPS (₹) | 10.31 | 7.98 | +29.2% | 6.76 | +52.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹334 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q4 FY26 results?
Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex. - The branded business, including U.S.
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
